BioCentury

7:00 AM GMT, Jul 7, 2003
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

2Q Approvals

2Q Approvals

Company Approvals
AstraZeneca (LSE:AZN; AZN) FDA approves Iressa gefitinib as third-line monotherapy in advanced non-small cell

Read the full 180 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.